Collegium Pharmaceutical, Inc. (COLL)
22.02
+0.18
(+0.82%)
USD |
NASDAQ |
Oct 02, 16:00
22.05
+0.03
(+0.14%)
Pre-Market: 20:00
Collegium Pharmaceutical Profit Margin (Quarterly) : -7.53% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.53% |
| March 31, 2026 | 7.49% |
| December 31, 2025 | 8.26% |
| September 30, 2025 | 15.05% |
| June 30, 2025 | 6.37% |
| March 31, 2025 | 1.36% |
| December 31, 2024 | 6.89% |
| September 30, 2024 | 5.86% |
| June 30, 2024 | 13.50% |
| March 31, 2024 | 19.12% |
| December 31, 2023 | 21.33% |
| September 30, 2023 | 15.09% |
| June 30, 2023 | 9.60% |
| March 31, 2023 | -12.04% |
| December 31, 2022 | -5.55% |
| September 30, 2022 | 0.36% |
| June 30, 2022 | -4.20% |
| March 31, 2022 | -15.60% |
| December 31, 2021 | -91.49% |
| September 30, 2021 | 10.21% |
| Date | Value |
|---|---|
| June 30, 2021 | 87.82% |
| March 31, 2021 | 17.85% |
| December 31, 2020 | 9.12% |
| September 30, 2020 | 14.25% |
| June 30, 2020 | 10.32% |
| March 31, 2020 | 0.59% |
| December 31, 2019 | -2.97% |
| September 30, 2019 | -8.38% |
| June 30, 2019 | -6.28% |
| March 31, 2019 | -13.02% |
| December 31, 2018 | 12.37% |
| September 30, 2018 | -23.52% |
| June 30, 2018 | -17.88% |
| March 31, 2018 | -29.26% |
| December 31, 2017 | -161.2% |
| September 30, 2017 | -111.0% |
| June 30, 2017 | -593.3% |
| March 31, 2017 | -1.06K% |
| December 31, 2016 | -2.12K% |
| September 30, 2016 | -6.48K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Innoviva, Inc. | -67.80% |
| Zevra Therapeutics, Inc. | 21.16% |
| ANI Pharmaceuticals, Inc. | 8.65% |
| Corcept Therapeutics, Inc. | 16.45% |
| Veru, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 16.72% |
| Return on Assets | 2.76% |
| Return on Invested Capital | 3.74% |
| Gross Profit Margin (Quarterly) | 55.18% |
| Operating Margin (Quarterly) | 2.94% |
| Return on Net Operating Assets | 3.70% |